<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04381026</url>
  </required_header>
  <id_info>
    <org_study_id>PRO_WH_HCT_2016.01</org_study_id>
    <nct_id>NCT04381026</nct_id>
  </id_info>
  <brief_title>Effects of a New Botanical Extracts Combination on Quality of Life in Menopausal Spanish Women</brief_title>
  <official_title>Study on the Effect of a Nutritional Supplement With Isoflavones on the Symptoms of Climacteric in Healthy Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nektium Pharma SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clínica Barem</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nektium Pharma SL</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to evaluate the beneficial effects and safety of a standardised
      botanical extract combination containing soy isoflavone extract, grains of paradise seed dry
      extract and pomegranate skin dry extract on health-related Quality of Life in healthy Spanish
      menopausal women with hot flashes, anxiety, and depressive symptoms using the self reported
      and validated Cervantes Scale.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fifty-seven outpatient women (45-65 years) with menstrual problems associated with
      climacteric syndrome were enrolled from April 2018 to April 2019 in the context of a
      prospective, placebo-controlled, double-blind study. Women were randomized to receive
      treatment with either the botanical combination (250 mg daily divided into two doses) or
      placebo for eight weeks. At the beginning and end of the study, health-related Quality of
      Life was assessed using the Cervantes Scale.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 19, 2017</start_date>
  <completion_date type="Actual">July 10, 2018</completion_date>
  <primary_completion_date type="Actual">June 6, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline to Week 8 in the global score of quality of life using the validated Cervantes Scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>To evaluate the improvement of quality of life after trial, a variable to quantify the percentage of reduction between after-treatment and before-treatment for global score (GS) in quality of life is generated: [Variation%=100 x ((initial GS value-final GS value)/ initial GS value)]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 8 in the Menopause-health score of quality of life using the validated Cervantes Scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>To evaluate the improvement of quality of life after trial, a variable to quantify the percentage of reduction between after-treatment and before-treatment for Menopause and health score (MHS) in quality of life is generated: [Variation%=100 x ((initial MHS value-final MHS value)/ initial MHS value)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 8 in the psychic score of quality of life using the validated Cervantes Scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>To evaluate the improvement of quality of life after trial, a variable to quantify the percentage of reduction between after-treatment and before-treatment for psychic score (PS) in quality of life is generated: [Variation%=100 x ((initial PS value-final PS value)/ initial PS value)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 8 in the sexuality-couple score of quality of life using the validated Cervantes Scale.</measure>
    <time_frame>8 weeks</time_frame>
    <description>To evaluate the improvement of quality of life after trial, a variable to quantify the percentage of reduction between after-treatment and before-treatment for sexuality-couple score (SCS) in quality of life is generated: [Variation%=100 x ((initial SCS value-final SCS value)/ initial SCS value)]</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline to week 8 in the bogy weight</measure>
    <time_frame>8 weeks</time_frame>
    <description>To evaluate the body weight reduccion, a variable to quantify the percentage of reduction between after-treatment and before-treatment in body weight (BW) is generated: [Variation%=100 x ((initial BW value-final BW value)/ initial BW value)]</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Menopause</condition>
  <condition>Dietary Supplements</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pill of 500 mg containing filler agent, two pills daily for eight weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group with botanical extracts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pill of 500 mg containing botanicals and filler agent, two pills daily for eight weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Botanical dry extracts combination</intervention_name>
    <description>Aframomum melgueta dry extract (50mg), Glycine max bean dry extract (100mg) and Punica granatum skin extract (100mg)</description>
    <arm_group_label>Treatment Group with botanical extracts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Filler agent</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women in the Climacteric Phase under medical criteria based on Health questionnaire,
             Blood and urine test.

          -  Informed consent to participate in the study.

        Exclusion Criteria:

          -  Hormone-related pathologies.

          -  Menopause from surgery origin.

          -  Family or personal history of endocrine cancer.

          -  Known hypersensitivity to gluten, soybeans, soy protein, dairy products, pomegranate
             or grains of paradise.

          -  Vegetarian diet or daily consumption of soya rich-products during the last year.

          -  Anovulatory treatment.

          -  Hormone replacement treatment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura López-Ríos, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nektium Pharma SL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Barem</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Las Palmas (Canary Islands)</state>
        <zip>35005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://aeem.es/para-profesionales/guias-clinicas/</url>
    <description>Clinical guides for menopause from AEEM</description>
  </link>
  <link>
    <url>https://www.elsevier.es/es-revista-clinica-e-investigacion-ginecologia-obstetricia-7-articulo-validez-fiabilidad-prueba-kupperman-S0210573X08730612</url>
    <description>paper on Validity and reliability of the Kupperman test [Spanish]</description>
  </link>
  <results_reference>
    <citation>Greene JG. Constructing a standard climacteric scale. Maturitas. 1998 May 20;29(1):25-31.</citation>
    <PMID>9643514</PMID>
  </results_reference>
  <results_reference>
    <citation>Buendía Bermejo J, Rodríguez Segarra R, Yubero Bascuñana N, Martínez Vizcaíno V. [Design and validation of a questionnaire in Spanish for measuring the quality of life in postmenopausal women: the MENCAV questionnaire]. Aten Primaria. 2001 Feb 15;27(2):94-100. Spanish.</citation>
    <PMID>11256098</PMID>
  </results_reference>
  <results_reference>
    <citation>Palacios S, Ferrer-Barriendos J, Parrilla JJ, Castelo-Branco C, Manubens M, Alberich X, Martí A; Grupo Cervantes. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]. Med Clin (Barc). 2004 Feb 21;122(6):205-11. Spanish.</citation>
    <PMID>15012887</PMID>
  </results_reference>
  <results_reference>
    <citation>Heinemann K, Ruebig A, Potthoff P, Schneider HP, Strelow F, Heinemann LA, Do MT. The Menopause Rating Scale (MRS) scale: a methodological review. Health Qual Life Outcomes. 2004 Sep 2;2:45.</citation>
    <PMID>15345062</PMID>
  </results_reference>
  <results_reference>
    <citation>Low Dog T. Menopause: a review of botanical dietary supplements. Am J Med. 2005 Dec 19;118 Suppl 12B:98-108. Review.</citation>
    <PMID>16414334</PMID>
  </results_reference>
  <results_reference>
    <citation>Tranche S, Brotons C, Pascual de la Pisa B, Macías R, Hevia E, Marzo-Castillejo M. Impact of a soy drink on climacteric symptoms: an open-label, crossover, randomized clinical trial. Gynecol Endocrinol. 2016 Jun;32(6):477-82. doi: 10.3109/09513590.2015.1132305. Epub 2016 Jan 25.</citation>
    <PMID>26806546</PMID>
  </results_reference>
  <results_reference>
    <citation>Kang SJ, Choi BR, Kim SH, Yi HY, Park HR, Kim DC, Choi SH, Han CH, Park SJ, Song CH, Ku SK, Lee YJ. Dried pomegranate potentiates anti-osteoporotic and anti-obesity activities of red clover dry extracts in ovariectomized rats. Nutrients. 2015 Apr 9;7(4):2622-47. doi: 10.3390/nu7042622.</citation>
    <PMID>25912038</PMID>
  </results_reference>
  <results_reference>
    <citation>Balk E, Chung M, Chew P, Ip S, Raman G, Kupelnick B, Tatsioni A, Sun Y, Wolk B, DeVine D, Lau J. Effects of soy on health outcomes. Evid Rep Technol Assess (Summ). 2005 Aug;(126):1-8. Review.</citation>
    <PMID>16194125</PMID>
  </results_reference>
  <results_reference>
    <citation>Ferrari A. Soy extract phytoestrogens with high dose of isoflavones for menopausal symptoms. J Obstet Gynaecol Res. 2009 Dec;35(6):1083-90. doi: 10.1111/j.1447-0756.2009.01058.x.</citation>
    <PMID>20025635</PMID>
  </results_reference>
  <results_reference>
    <citation>Klein MA, Nahin RL, Messina MJ, Rader JI, Thompson LU, Badger TM, Dwyer JT, Kim YS, Pontzer CH, Starke-Reed PE, Weaver CM. Guidance from an NIH workshop on designing, implementing, and reporting clinical studies of soy interventions. J Nutr. 2010 Jun;140(6):1192S-1204S. doi: 10.3945/jn.110.121830. Epub 2010 Apr 14.</citation>
    <PMID>20392880</PMID>
  </results_reference>
  <results_reference>
    <citation>Munro IC, Harwood M, Hlywka JJ, Stephen AM, Doull J, Flamm WG, Adlercreutz H. Soy isoflavones: a safety review. Nutr Rev. 2003 Jan;61(1):1-33. Review.</citation>
    <PMID>12638461</PMID>
  </results_reference>
  <results_reference>
    <citation>Satpathy S, Patra A, Purohit AP. Estrogenic activity of Punica granatum L. peel extract. Asian Pacific J. Reprod. 2013; 2(1): 19-24</citation>
  </results_reference>
  <results_reference>
    <citation>Bialonska D, Ramnani P, Kasimsetty SG, Muntha KR, Gibson GR, Ferreira D. The influence of pomegranate by-product and punicalagins on selected groups of human intestinal microbiota. Int J Food Microbiol. 2010 Jun 15;140(2-3):175-82. doi: 10.1016/j.ijfoodmicro.2010.03.038. Epub 2010 Apr 2.</citation>
    <PMID>20452076</PMID>
  </results_reference>
  <results_reference>
    <citation>Mori-Okamoto J, Otawara-Hamamoto Y, Yamato H, Yoshimura H. Pomegranate extract improves a depressive state and bone properties in menopausal syndrome model ovariectomized mice. J Ethnopharmacol. 2004 May;92(1):93-101.</citation>
    <PMID>15099854</PMID>
  </results_reference>
  <results_reference>
    <citation>Ilic NM, Dey M, Poulev AA, Logendra S, Kuhn PE, Raskin I. Anti-inflammatory activity of grains of paradise (Aframomum melegueta Schum) extract. J Agric Food Chem. 2014 Oct 29;62(43):10452-7. doi: 10.1021/jf5026086. Epub 2014 Oct 20.</citation>
    <PMID>25293633</PMID>
  </results_reference>
  <results_reference>
    <citation>Sugita J, Yoneshiro T, Hatano T, Aita S, Ikemoto T, Uchiwa H, Iwanaga T, Kameya T, Kawai Y, Saito M. Grains of paradise (Aframomum melegueta) extract activates brown adipose tissue and increases whole-body energy expenditure in men. Br J Nutr. 2013 Aug;110(4):733-8. doi: 10.1017/S0007114512005715. Epub 2013 Jan 11.</citation>
    <PMID>23308394</PMID>
  </results_reference>
  <results_reference>
    <citation>Igwe SA, Emeruwa IC, Modie JA. Ocular toxicity of Afromomum melegueta (alligator pepper) on healthy Igbos of Nigeria. J Ethnopharmacol. 1999 Jun;65(3):203-6.</citation>
    <PMID>10404417</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Menopause</keyword>
  <keyword>Hot flushes</keyword>
  <keyword>Isoflavones</keyword>
  <keyword>Aframomum melegueta extract</keyword>
  <keyword>Punica granatum extract</keyword>
  <keyword>Cervantes Scale</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

